Market reactionShares fell 10% on Nov 5.
MAIA Biotechnology is a clinical-stage company developing ateganosine, a telomere-targeting drug for advanced non-small cell lung cancer that no longer responds to immunotherapy and chemotherapy; it is not approved.
MAIA's case rests on ateganosine (THIO), a telomere-targeting drug given before a checkpoint inhibitor, in third-line non-small cell lung cancer. In the small, uncontrolled THIO-101 Phase 2, median overall survival was 17.8 months, against roughly 5 to 6 months historically. The Phase 3 THIO-104 against chemotherapy began in 2025, and with $27.6 million in cash MAIA says it will need to raise more money.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: THIO-104 shows benefit over chemotherapy
Does ateganosine improve disease control and progression-free survival over chemotherapy?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ateganosine's THIO-104 Phase 3 against chemotherapy is enrolling, and MAIA says it must raise more money
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.